瑞康医药 - Financials

瑞康医药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	8.0B	8.0B	12.3B	21.1B	27.2B
Revenue Growth %	-0.8%	-34.7%	-41.5%	-22.7%	--
Total Revenue	8.0B	8.0B	12.3B	21.1B	27.2B
Cost Of Revenue	7.1B	7.2B	10.6B	17.2B	22.2B
+Gross Profit	876.0M	827.0M	1.7B	3.8B	5.0B
Gross Margin %	11.0%	10.3%	13.6%	18.2%	18.4%
Total Operating Cost	8.1B	8.3B	13.1B	20.8B	26.5B
Selling Expenses	360.0M	432.0M	847.0M	1.7B	2.2B
Admin Expenses	395.0M	408.0M	700.0M	1.0B	1.2B
Rd Expenses	10.0M	14.6M	22.7M	11.6M	8.9M
Finance Expenses	127.0M	133.0M	362.0M	463.0M	607.0M
+Operating Income	25.5M	-127.0M	-1.7B	499.0M	956.0M
Operating Margin %	0.3%	-1.6%	-13.9%	2.4%	3.5%
Non Operating Income	20.3M	2.9M	1.1M	10.5M	15.6M
Non Operating Expenses	4.3M	11.7M	28.4M	44.6M	54.8M
Investment Income	96.2M	409.0M	-481.0M	115.0M	227.0M
Fair Value Change Income	30.6M	-229.0M	-431.0M	93.5M	-87.0M
Asset Disposal Income	18.9M	-7.9M	-995,300	3.1M	3.8M
Asset Impairment Loss	--	33.5M	218.0M	49.9M	25.7M
Other Income	2.4M	8.8M	16.9M	63.9M	68.9M
Income Before Tax	41.6M	-135.0M	-1.7B	465.0M	916.0M
Income Tax	551,000	-167.0M	-4.9M	83.0M	291.0M
+Net Income	41.0M	32.0M	-1.7B	382.0M	625.0M
Net Margin %	0.5%	0.4%	-14.1%	1.8%	2.3%
Net Income Attributable	20.6M	20.3M	-1.8B	131.0M	261.0M
Minority Interest	20.4M	11.7M	92.2M	251.0M	364.0M
Eps Basic	0.01	0.01	-1.24	0.09	0.18
Eps Diluted	0.01	0.01	-1.24	0.09	0.18

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	5.0B	5.1B	5.3B	4.6B	5.8B
Trading Financial Assets	--	--	--	--	40.8M
Accounts Receivable	3.9B	3.8B	4.1B	10.3B	13.7B
Notes Receivable	189.0M	217.0M	202.0M	723.0M	1.0B
Notes And Accounts Receivable	4.1B	4.0B	4.3B	11.0B	14.7B
Prepayments	48.2M	97.4M	192.0M	641.0M	919.0M
Inventory	735.0M	1.1B	955.0M	2.1B	2.9B
Total Current Assets	11.1B	11.5B	12.8B	20.7B	26.6B
Long Term Equity Investment	532.0M	655.0M	436.0M	639.0M	653.0M
Fixed Assets	--	1.8B	2.0B	1.9B	2.3B
Fixed Assets Total	1.9B	1.8B	2.0B	1.9B	2.3B
Construction In Progress	--	429.0M	315.0M	550.0M	871.0M
Construction In Progress Total	307.0M	429.0M	315.0M	550.0M	871.0M
Intangible Assets	441.0M	552.0M	624.0M	478.0M	320.0M
Long Term Deferred Expenses	39.2M	60.9M	89.9M	125.0M	139.0M
Total Non Current Assets	5.0B	5.2B	5.5B	5.7B	5.6B
Total Assets	16.0B	16.7B	18.3B	26.4B	32.1B
Short Term Borrowings	6.1B	6.6B	3.8B	4.2B	9.5B
Accounts Payable	2.8B	3.3B	2.6B	3.4B	4.6B
Advance Receipts	11.1M	--	627,200	--	--
Contract Liabilities	14.0M	29.1M	31.8M	175.0M	234.0M
Total Current Liabilities	9.9B	10.8B	12.5B	16.5B	21.2B
Long Term Borrowings	327.0M	261.0M	67.2M	48.5M	6.7M
Total Non Current Liabilities	384.0M	311.0M	112.0M	196.0M	454.0M
Total Liabilities	10.3B	11.1B	12.6B	16.7B	21.6B
Paid In Capital	1.5B	1.5B	1.5B	1.5B	1.5B
Capital Reserve	3.6B	3.7B	3.7B	4.0B	4.0B
Surplus Reserve	167.0M	160.0M	153.0M	153.0M	135.0M
Retained Earnings	242.0M	294.0M	280.0M	2.1B	2.0B
Minority Equity	160.0M	189.0M	344.0M	2.1B	3.0B
Equity Attributable	5.5B	5.4B	5.4B	7.6B	7.5B
Total Equity	5.7B	5.6B	5.8B	9.7B	10.5B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	8.6B	8.7B	14.6B	23.7B	29.8B
Tax Refunds Received	384,900	22.5M	89.3M	30.1M	27.5M
Total Operating Cash Inflow	9.6B	9.3B	15.3B	25.8B	33.3B
Cash Paid For Goods	8.0B	7.7B	12.0B	19.9B	23.4B
Cash Paid To Employees	311.0M	306.0M	533.0M	750.0M	799.0M
Taxes Paid	166.0M	158.0M	488.0M	959.0M	1.1B
Total Operating Cash Outflow	9.4B	9.2B	14.8B	25.3B	32.8B
Operating Cash Flow	160.0M	82.5M	523.0M	443.0M	415.0M
Total Investing Cash Inflow	1.1B	1.5B	2.5B	280.0M	614.0M
Total Investing Cash Outflow	858.0M	927.0M	1.9B	864.0M	1.6B
Investing Cash Flow	204.0M	580.0M	593.0M	-584.0M	-973.0M
Cash From Borrowings	2.7B	5.4B	5.9B	6.5B	9.6B
Dividends And Interest Paid	199.0M	282.0M	233.0M	383.0M	376.0M
Debt Repayments	3.0B	4.0B	4.3B	6.8B	9.8B
Total Financing Cash Inflow	21.4B	26.2B	17.5B	19.6B	22.1B
Total Financing Cash Outflow	21.5B	26.9B	19.0B	19.6B	23.2B
Financing Cash Flow	-146.0M	-677.0M	-1.5B	-50.4M	-1.1B
Net Change In Cash	218.0M	-15.2M	-349.0M	-191.0M	-1.6B
Ending Cash Balance	690.0M	472.0M	487.0M	836.0M	1.0B
Capex	112.0M	298.0M	171.0M	461.0M	640.0M